Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Sep 27, 2006
Positive Preclinical Results for NNZ-3006
Sep 22, 2006
Neuren Share Purchase Plan Disclosures
Sep 22, 2006
Update for Shareholders Sept 2006
Sep 19, 2006
Appendix 3B - Placement shares
Sep 19, 2006
A$6.0 million Share placement & Share Purchase Plan
Sep 12, 2006
Half Yearly Report
Sep 04, 2006
Glypromate Phase 2 Trial with US Army
Aug 22, 2006
Glypromate Phase 2 trial final results
Aug 21, 2006
ASX Waiver for reporting results of IFRS transition periods
Aug 14, 2006
Neuren to present NNZ2566 Phase 2 Strategy
Previous
1
2
3
4
5
Next
